Cassava sciences announces agreement with fda on special protocol assessments (spa) for its phase 3 studies of simufilam for the treatment of alzheimer's disease

Phase 3 study initiation still expected fall 2021 phase 3 study initiation still expected fall 2021

SAVA Ratings Summary

SAVA Quant Ranking